4D Molecular Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From 4D Molecular Therapeutics Inc.
Scrip Asks...What Does 2023 Hold For Biopharma? Part 2: M&A And Partnering
Deal-making between big pharma and biotech looks set to rise with a looming patent cliff increasing the need for the former to replenish its pipelines. Meanwhile, biotechs need partners to help them advance amid the ongoing big freeze on raising cash on public markets.
Regenxbio: On The Cusp Of Becoming A Commercial Gene Therapy Player
Partnered with AbbVie on a wet AMD gene therapy, Regenxbio is also advancing wholly owned candidates for Duchenne muscular dystrophy and MPS I and MPS II.
Sangamo's Fabry Gene Therapy May Be A STAAR In The Making
The US biotech has presented interesting preliminary data from the first four patients treated in the Phase I/II STAAR study evaluating isaralgagene civaparvovec for Fabry.
Finance Watch: 2021 Is Now Two Away From 100 Biopharma IPOs
Public Company Edition: Entrada’s initial public offering grossed $181.5m while Aura raised $75.6m and Biofrontera brought in $18m. Also, AnaptysBio received $250m in Jemperli royalty deal and 4D Molecular Therapeutics grossed $118.8m in a follow-on offering.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.